Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry

Parenteral prostacyclin analogues (PPA) are recommended for pulmonary arterial hypertension (PAH) patients at intermediate-high or high risk, yet supporting evidence remains limited. We retrospectively analyzed pretreated patients with idiopathic/heritable/drug-associated PAH (I/H/D-PAH), connective tissue disease-associated PAH (CTD-PAH), or congenital heart disease-associated PAH (CHD-PAH) from the COMPERA registry who received add-on PPA therapy. Among 495 patients, all pretreated with

• Tello, K.
• Delcroix, M.
• Pausch, C.
• Huscher, D.
• Pittrow, D.
• Ardeschir Ghofrani, H.
• Badagliacca, R.
• Vonk-Noordegraaf, A.
• Kopec, G.
• Halank, M.
• Ewert, R.
• Klose, H.
• Grünig, E.
• Skride, A.
• Ulrich, S.
• Stadler, S.
• Scelsi, L.
• Pfeuffer-Jovic, E.
• Hoeper, M. M.
• Olsson, K. M.